Galectin Therapeutics (GALT) Return on Capital Employed (2011 - 2026)

Galectin Therapeutics' Return on Capital Employed history runs 16 years deep, the most recent figure standing at 157.32% for Q1 2026.

• In Q1 2026, Return on Capital Employed fell 19912.0% year-over-year to 157.32%; the TTM figure through Mar 2026 stood at 157.32% (down 19912.0% YoY), while the FY2025 annual figure was 191.59%, down 52939.0% from the prior year.
• Return on Capital Employed was 157.32% for Q1 2026 at Galectin Therapeutics, up from 245.88% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 348.51% in Q4 2024 to a low of 1899.27% in Q2 2025.
• Historically, Return on Capital Employed has averaged 382.77% across 5 years, with a median of 285.45% in 2022.
• Biggest YoY gain for Return on Capital Employed was 131876 bps in 2025; the steepest drop was 157295 bps in 2025.
• A 5-year view of Return on Capital Employed shows it stood at 582.19% in 2022, then jumped by 31 bps to 400.53% in 2023, then jumped by 187 bps to 348.51% in 2024, then tumbled by 171 bps to 245.88% in 2025, then jumped by 36 bps to 157.32% in 2026.
• The last three Return on Capital Employed figures came in at 157.32% (Q1 2026), 245.88% (Q4 2025), and 23.85% (Q3 2025), per Business Quant data.